Abstract
The effect of chronic bromocriptine administration (7.5–20 mg/day for 1 -32 months) on the size of “nonsecreting” pituitary adenomas (NPA) was studied in 20 patients. Brain computed tomography showed a marked reduction of the adenoma in one patient after 1 month of treatment (7.5 mg/day); further scans taken 2 and 15 months later, under the same bromocriptine dose, did not show any other variations in the tumoral mass. In the remaining 19 patients, no changes in tumor size were documented by CT during the treatment. Four patients had a worsening of visual fields during bromocriptine administration and they were referred for neurosurgery. In conclusion, bromocriptine was ineffective in reducing tumor size in all but one patient with NPA and; in some cases, it did not prevent tumor growth as is suggested by the worsening of visual fields. Thus, bromocriptine treatment, at least at the doses capable of shrinking macroprolactino-mas, seems to be of limited value in patients with NPA.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Chiodini P.G., Liuzzi A., Verde G., Cozzi R., Silvestrini F., Marsili M.T., Horowski R., Passerini F., Luccarelli G., Borghi G. Size reduction of a prolactin secreting adenoma during a long-term treatment with a dopamine agonist, lisuride. International Symposium on Pituitary Microadenomas (Serono Symposia), Milan, Italy, 1978 (Abstract 64).
Chiodini P.G., Liuzzi A., Cozzi R., Verde G., Oppizzi G., Dallabonzana D., Spelta V., Silvestrini F., Borghi G., Luccarelli G., Rainer E., Horowski R. Size reduction of macroprolactinomas by bromocriptine or lisuride treatment. J. Clin. Endocrinol. Metab. 53: 737, 1981.
Nissim M., Ambrosi V., Bernasconi V., Giannattasio G., Giovanelli M.A., Bassetti M., Vaccari U., Moriondo P., Spada A., Travaglini P., Faglia G. Bromocriptine treatment of macroprolactinomas: studies on the time course of tumor shrinkage and morphology. J. Endocrinol. Invest. 5: 409, 1982.
Spark R.F., Baker R., Bienfang D.C., Bergland R. Bromocriptine reduces pituitary tumor size. Requiem for pituitary surgery? JAMA 247: 311, 1982.
Wass J.A.H., Williams J., Charlesworth M., Kingsley D.P.E. Halliday A.M., Doniach I., Rees LH., McDonald W.I., Besser G.M. Bromocriptine in management of large pituitary tumours. Br. Med. J. 284: 1908, 1982.
Johnston D.G., Hall K., McGregor A., Ross W.M., Kendall-Taylor P., Hall R. Bromocriptine therapy for “nonfunctioning” pituitary tumors. Am. J. Med. 71: 1059, 1981.
Wollesen F., Andersen T., Karle A. Size reduction of extrasellar pituitary tumors during bromocriptine treatment. Quantitation of effect on different types of tumors. Ann. Intern. Med. 96: 281, 1982.
Barrow D.L, Tindall G.T., Kovacs K., Thorner M.O, Horvath E., Hoffman J.C. Jr. Clinical and pathological effects of bromocriptine on prolactin-secreting and other pituitary tumors. J. Neurosurg. 60: 1, 1984.
Serri O., Marchisio A.M., Collu R., Somma M. Dopaminergic receptors in normal and tumoral human pituitary. 63rd Annual Meeting of the Endocrine Society, Cincinnati, June 17-19, 1981 (Abstract 343).
Author information
Authors and Affiliations
Additional information
Supported by CNR, Special Project “Control of Neoplastic Growth”, grant no. 830085396.
Rights and permissions
About this article
Cite this article
Verde, G., Oppizzi, G., Chiodini, P.G. et al. Effect of chronic bromocriptine administration on tumor size in patients with “nonsecreting” pituitary adenomas. J Endocrinol Invest 8, 113–115 (1985). https://doi.org/10.1007/BF03350660
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/BF03350660